Opinion

Video

Widening the Therapeutic Window in The Management of Parkinson’s Disease

Author(s):

Stuart H. Isaacson, MD, FAAN,Rajesh Pahwa, MD

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Timecodes:

1:20 Long-term challenges

2:58 Fluctuations in benefits

6:35 Therapeutic window

11:40 Amantadine ER for PD

14:33 Dyskinesia and treatment

18:18 Amantadine patients

23:14 Amantadine formulations

27:59 Early treatment & future

Related Videos
Related Content
Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes
December 20th 2024

Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes

Marco Meglio
Multisymptomatic Care in Parkinson's Disease
September 4th 2024

Multisymptomatic Care in Parkinson's Disease

Stuart H. Isaacson, MD, FAAN Rajesh Pahwa, MD Jennifer G. Goldman, MD, MS
Carole Ho, MD (Credit: Denali)
December 11th 2024

First Patient Treated in Phase 2a Trial of Investigational BIIB122 for LRRK2-Associated Parkinson Disease

Isabella Ciccone, MPH
Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease
April 9th 2024

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Anne Marie Morse, DO, FAASM NeurologyLive® Staff
Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
December 3rd 2024

Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease

Marco Meglio
Parkinson Agent HL192 Successfully Completes Phase 1 First-In-Human Study
November 26th 2024

Parkinson Agent HL192 Successfully Completes Phase 1 First-In-Human Study

Marco Meglio
© 2024 MJH Life Sciences

All rights reserved.